Business
Arcutis’ ZORYVE® (roflumilast) Cream Receives Strong Recommendation in American Academy of Dermatology First-Ever Pediatric Atopic Dermatitis Guidelines
Strong recommendation with high certainty of clinical evidence underscores proven efficacy, safety, and tolerability of ZORYVE cream as a steroid-free topical phosphodiesterase type 4 (PDE4) inhibitorAtopic dermatitis affects approximately 9.6 million children in the United States WESTLAKE VILLAGE, Calif., April 22, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company dedicated to developing meaningful innovations in immuno-dermatolo
About this update from Arcutis Biotherapeutics, Inc.
[{"type":"image","alt":"Arcutis Biotherapeutics, Inc.","displaySize":"","headline":null,"caption":"Arcutis Biotherapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":54,"url":"https://media.zenfs.com/en/globenewswire.com/7ec1ad75d1b30c39742ed46c38e50fa3"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/NsgskJmcmYR2weZA9OX0jg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTc2/https://media.zenfs.com/en/globenewswire.com/7ec1ad75d1b30c39742ed46c38e50fa3","width":300,"height":54}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Strong recommendation with high certainty of clinical evidence underscores proven efficacy, safety, and tolerability of ZORYVE cream as a steroid-free topical phosphodiesterase type 4 (PDE4) inhibitor","length":200,"tagName":"p"}]},{"val":[{"type":"text","content":"Atopic dermatitis affects approximately 9.6 million children in the United States","length":81,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":281,"olType":false},{"type":"text","content":"WESTLAKE VILLAGE, Calif., April 22, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company dedicated to developing meaningful innovations in immuno-dermatology, today announced that ZORYVE® (roflumilast) cream has received a strong recommendation, with high certainty of clinical evidence, in the American Academy of Dermatology (AAD) clinical practice guidelines for the management of pediatric atopic dermatitis.","length":475,"tagName":"p"},{"type":"text","content":"The AAD’s evidence-based guidelines recommend the use of ZORYVE cream 0.05% for children aged 2-5 years and ZORYVE cream 0.15% for children aged 6 years and older with mild to moderate atopic dermatitis, recognizing its efficacy, safety, and tolerability. The recommendation reinforces ZORYVE’s ability to deliver clinically meaningful improvements in disease severity and itch with very low rates of treatment discontinuation, offering an effective topical suitable for long-term use anywhere on the body in both children and adolescents. In clinical trials, the most common adverse reactions reported (≥1%) for ZORYVE cream 0.05% for pediatric patients 2 to 5 years of age with atopic dermatitis were upper respiratory tract infection, diarrhea, vomiting, rhinitis, conjunctivitis, and headache. The ...